DOCSLIB.ORG

Curriculum Vitae: Joseph J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae: Joseph J August 9, 2016 CURRICULUM VITAE: JOSEPH J. ERON, JR. PERSONAL INFORMATION: Name: Joseph J. Eron, Jr. Medical License: NC 35891 Work Address: 130 Mason Farm Rd Ste 2110 Bioinformatics Bldg Home Address: 511 Quinn Court Chapel Hill NC 27599-7215 Chapel Hill, NC 27516 Phone: 919-843-2722 (work) 919-933-2655 (home) Date of Birth: September 8, 1958 Place of Birth: Syracuse, New York Marital Status: Married EDUCATION: 1989-1992 Clinical Fellow in Medicine, Infectious Diseases, Massachusetts General Hospital, Harvard Medical School 1991 Diplomate, American Board of Internal Medicine, Subspecialty of Infectious Diseases 1987 Diplomate, American Board of Internal Medicine 1986-1987 Third Year Resident in Internal Medicine, Massachusetts General Hospital, Harvard Medical School 1985-1986 Second Year Resident in Internal Medicine, Massachusetts General Hospital, Harvard Medical School 1984-1985 First Year Resident in Internal Medicine, Massachusetts General Hospital, Harvard Medical School 1984 Diplomate, National Board of Medical Examiners 1980-1984 Doctor of Medicine, Harvard Medical School 1976-1980 Bachelor of Science, Biochemistry, Harpur College, State University of New York at Binghamton EMPLOYMENT: 2009-Present Adjunct Professor of Epidemiology, School of Public Health, UNC-CH 2005-Present Professor of Medicine, School of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill 1998-2005 Associate Professor of Medicine, School of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill 1992-1998 Assistant Professor of Medicine, School of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill 1987-1989 Director of Internal Medicine, Zuni Indian Health Service Hospital, Zuni, New Mexico PROFESSIONAL EXPERIENCE: 2001-Present Principle Investigator AIDS Clinical Research Group, UNC-CH 1998-Present Director, Clinical Core, UNC Center for AIDS Research, UNC-CH 1995-2012 Associate Director, GCRC/Clinical Trials Research Unit, UNC-CH 1992-2001 Co-Principal Investigator, AIDS Clinical Research Group, UNC-CH 1992-1998 Director of Clinic, Division of Infectious Diseases, UNC-CH 1992 Medical License #35891, North Carolina, 1989-1992 Research Fellow in Medicine, Harvard Medical School 1984-1987 Clinical Fellow in Medicine, Harvard Medical School 1984 Medical License, Commonwealth of Massachusetts HONORS AND AWARDS: 2013 HIV Medicine Association/Infectious Diseases Society of America – HIV Clinical Educator Award 2005 International Association of Physicians in AIDS Care (IAPAC), Lifetime Member 2005 Edward Weisband Distinguished Alumnus Award for Public Service, Binghamton Last Edited Tuesday, August 9, 2016 Page 1 of 35 August 9, 2016 2005 UNC-CH Distinguished Teaching Award for Post-Baccalaureate Instruction 2004 NC Governor’s World AIDS Day, Volunteer Service Award, Clinicians 2000 Alpha Omega Alpha, Medical Honor Society, (nominated by UNC Medical Students) 1995 UNC-CH Junior Faculty Development Award 1994 Medicine Housestaff Teaching Award at University of North Carolina, Chapel Hill 1991-1993 National Research Service Award (NRSA), NIAID (F32AI08263)-01A1 1979 Phi Beta Kappa 1976-1980 Aswad Foundation Award, Excellence in Premedical Education, State University of New York at Binghamton 1976-80 Outstanding Performance at Harpur College BIBLIOGRAPHY: Books and Chapters: 1. Eron JJ, Smith KY, Squires KE, Editors in Chief, CCO InPractice HIV, clinicaloptions.com/inpractice 2011 2. KB Patterson and Eron JJ. HIV and the Heart. In M.S. Runge, E.M.Ohman (Eds.), Netter’s Cardiology, Chapter 59:578- 585. New Jersey: Icon Learning Systems, 2004. 3. Eron JJ. Septicemia. In M.S. Runge, M.A. Greganti (Eds.), Netter’s Internal Medicine, Chapter 82:545-549. New Jersey: Icon Learning Systems, 2003. 4. Eron JJ. Herpes Simplex Encephalitis. In M.S. Runge, M.A. Greganti (Eds.), Netter’s Internal Medicine, Chapter 74:492-495. New Jersey: Icon Learning Systems, 2003. 5. Daar ES, Eron JJ, Gallant JE, Grant RM, et al. Human Immunodeficiency Virus (HIV) In V.L. Yu, R. Weber, D. Raoult (Eds.), Antimicrobial Therapy and Vaccines, Volume I:Microbes, Section VI:Viruses:1249-1315. Pennsylvania: ESun Technologies, LCC, 2003. 6. Eron JJ, Dolin, R, Masur H, Saag M. Lamivudine. In AIDS Therapy, 72-86. New York: Churchill Livingstone, 1999. 7. Eron JJ and Hirsch MS. Antiviral Therapy of HIV Infection In K. Holmes, (Ed.), Sexually Transmitted Diseases, 3rd Edition, Chapter 74:987-994. 8. Fiscus SA and Eron JJ. Molecular Biological Techniques for the Detection of Human Immunodeficiency Virus Type 1 In R. Heim, L. Silverman (Eds.), Molecular Pathology: Approaches to diagnosing human disease in the clinical laboratory, 207-245. North Carolina: Carolina Academic Press, 1994. REFERRED JOURNALS: In Press or Published: Original Reports 1. Chan ES, Landay AL, Brown TT, Ribaudo HJ, Mirmonsef P, Ofotokun I, Weitzmann MN, Martinson J, Klingman KL, Eron JJ, Fichtenbaum CJ, Plants J, Taiwo BO. Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS. 2016 Aug 24;30(13):2091-7. PMID: 27281061; PMCID: PMC4966543. 2. Crane HM, Nance RM, Merrill JO, Hutton H, Chander G, McCaul ME, Mathews WC, Fredericksen R, Simoni JM, Mayer K, Mugavero MJ, Willig JH, Burkholder G, Drozd DR, Mimiaga M, Lau B, Kim HN, Cropsey K, Moore RD, Christopoulos K, Geng E, Eron JJ, Napravnik S, Kitahata MM, Saag MS, Delaney JA. Not all non-drinkers with HIV are equal: demographic and clinical comparisons among current non-drinkers with and without a history of prior alcohol use disorders. AIDS Care. 2016 Aug 2:1-8. PMID: 27482893. 3. Kim HN, Nance R, Van Rompaey S, Delaney JC, Crane HM, Cachay ER, Geng E, Boswell SL, Rodriguez B, Eron JJ, Saag M, Moore RD, Kitahata MM. Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):437-43. PMID: 26990826; PMC4925189. 4. Okeke NL, Davy T, Eron JJ, Napravnik S. Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. Clin Infect Dis. 2016 Jul 15;63(2):242-8. PMID: 27090989. 5. Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar- Manning E, Sabin D, McCauley M, Gamble T, Zhang XC, Eron JJ, Gallant JE, Kumwenda J, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim J, Badal-Faesen S, Akelo V, Hosseinipour MC, Santos BR, Godbole SV, Last Edited Tuesday, August 9, 2016 Page 2 of 35 August 9, 2016 Pilotto JH, Grinsztejn B, Panchia R, Mayer KH, Chen YQ, Cohen MS, Eshleman SH. Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):304-9. PMCID: PMC4911290. 6. Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Rusin D, Eron JJ, Taiwo BO; ACTG 5303 team. Neurocognition in maraviroc- compared to tenofovir: a double blind randomized placebo controlled trial ACTG A5303. AIDS. 2016 Jun 20 PMID: 27333088. 7. Rutstein SE, Hosseinipour MC, Weinberger M, Wheeler SB, Biddle AK, Wallis CL, Balakrishnan P, Mellors JW, Morgado M, Saravanan S, Tripathy S, Vardhanabhuti S, Eron JJ, Miller WC. Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm. BMC Infect Dis. 2016 Jun 13;16(1):280. PMCID: PMC4906700. 8. Rhee SY, Sankaran K, Varghese V, Winters MA, Hurt CB, Eron JJ, Parkin N, Holmes SP, Holodniy M, Shafer RW. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. J Virol. 2016 Jun 10;90(13):6058-70. PMID: 27099321. 9. Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):214-21. PMCID: PMC4866894. 10. Sen S, An H, Menezes P, Oakes J, Eron J, Lin W, Robertson K, Powers W. Increased Cortical Cerebral Blood Flow in Asymptomatic Human Immunodeficiency Virus-Infected Subjects. J Stroke Cerebrovasc Dis. 2016 May 5. pii: S1052-3057(16)00198-1. PMID: 27160382. 11. Bednar MM, Hauser BM, Zhou S, Jacobson JM, Eron JJ Jr, Frank I, Swanstrom R. Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation. J Infect Dis. 2016 Apr 30. PMID: 27132284. 12. Chander G, Monroe AK, Crane HM, Hutton HE, Saag MS, Cropsey K, Eron JJ, Quinlivan EB, Geng E, Mathews WC, Boswell S, Rodriquez B, Ellison M, Kitahata MM, Moore RD, McCaul ME. HIV primary care providers-Screening, knowledge, attitudes and behaviors related to alcohol interventions. Drug Alcohol Depend. 2016 Apr 1;161:59-66. PMID: 26857898. 13. Honeycutt JB, Wahl A, Baker C, Spagnuolo RA, Foster J, Zakharova O, Wietgrefe S, Caro-Vegas C, Madden V, Sharpe G, Haase AT, Eron JJ, Garcia JV. Macrophages sustain HIV replication in vivo independently of T cells. J Clin Invest. 2016 Apr 1;126(4):1353-66. PubMed PMID: 26950420. 14. Lesko CR, Cole SR, Hall HI, Westreich D, Miller WC, Eron JJ, Li J, Mugavero MJ; CNICS Investigators. The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009-11. Int J Epidemiol. 2016 Feb;45(1):140-50. PMID: 26772869.
Load more

Recommended publications
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • This Project Has Been Supported with Unrestriced Grants from Abbvie Gilead Sciences HEXAL Janssen-Cilag MSD Viiv Healthcare By
    This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • Synthetic Compounds with 2-Amino-1, 3, 4-Thiadiazole Moiety
    molecules Review Synthetic Compounds with 2-Amino-1,3,4-Thiadiazole Moiety Against Viral Infections Georgeta Serban Pharmaceutical Chemistry Department, Faculty of Medicine and Pharmacy, University of Oradea, 29 Nicolae Jiga, 410028 Oradea, Romania; [email protected]; Tel.: +4-0756-276-377 Academic Editor: Antonio Carta Received: 29 January 2020; Accepted: 18 February 2020; Published: 19 February 2020 Abstract: Viral infections have resulted in millions of victims in human history. Although great efforts have been made to find effective medication, there are still no drugs that truly cure viral infections. There are currently approximately 90 drugs approved for the treatment of human viral infections. As resistance toward available antiviral drugs has become a global threat to health, there is an intrinsic need to identify new scaffolds that are useful in discovering innovative, less toxic and highly active antiviral agents. 1,3,4-Thiadiazole derivatives have been extensively studied due to their pharmacological profile, physicochemical and pharmacokinetic properties. This review provides an overview of the various synthetic compounds containing the 2-amino-1,3,4-thiadiazole moiety that has been evaluated for antiviral activity against several viral strains and could be considered possible prototypes for the development of new antiviral drugs. Keywords: 2-amino-1,3,4-thiadiazole; viral infections; antiviral agents; drug resistance; inhibitory concentration; mechanism of action 1. Human Viral Infections Viruses are the smallest among
    [Show full text]
  • Phosphinic Acids: Current Status and Potential for Drug Discovery
    REVIEWS Drug Discovery Today Volume 24, Number 3 March 2019 Reviews POST SCREEN Phosphinic acids: current status and potential for drug discovery 1,2,3 3,4 2 2 Moaz M. Abdou , Paul M. O’Neill , Eric Amigues and Magdalini Matziari 1 Egyptian Petroleum Research Institute, Nasr City, PO 11727, Cairo, Egypt 2 Department of Chemistry, Xi’an Jiaotong Liverpool University, Suzhou, Jiangsu 215123, PR China 3 Department of Chemistry, University of Liverpool, Liverpool, L69 7ZD, UK 4 Department of Pharmacology, School of Biomedical Sciences, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, UK Phosphinic acid derivatives exhibit diverse biological activities and a high degree of structural diversity, rendering them a versatile tool in the development of new medicinal agents. Pronounced recent progress, coupled with previous research findings, highlights the impact of this moiety in medicinal chemistry. Here, we highlight the most important breakthroughs made with phosphinates with a range of pharmacological activities against many diseases, including anti-inflammatory, anti-Alzheimer, antiparasitic, antihepatitis, antiproliferative, anti-influenza, anti-HIV, antimalarial, and antimicrobial agents. We also provide the current status of the corresponding prodrugs, drug-delivery systems, and drug applications of phosphinic acids in the clinical stage Introduction and scope On searching ‘phosphinic acid’ as a keyword in any chemistry The phosphinic acid chemistry story began with the pioneering database; a countless amount of literature references; journal work of August Wilhelm Hofmann in 1855 on methylphosphinic articles; books; and patents appear as proof of its importance acid [1]. The broad biological applications of phosphinic acids are in chemical research; thus; it is impractical to survey the litera- driven by their four combined features: tetrahedral transition state ture of phosphinic acids without narrowing the search to specific resemblance; ability to form electrostatic interactions;, hydrogen perspectives.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Drug Interactions Between Hormonal Contraceptives and Antiretrovirals
    Drug interactions between hormonal contraceptives and antiretrovirals Kavita Nandaa, Gretchen S. Stuartb, Jennifer Robinsonc, Andrew L. Grayd, Naomi K. Teppere and Mary E. Gaffieldf Objective: To summarize published evidence on drug interactions between hormonal contraceptives and antiretrovirals. Design: Systematic review of the published literature. Methods: We searched PubMed, POPLINE, and EMBASE for peer-reviewed publi- cations of studies (in any language) from inception to 21 September 2015. We included studies of women using hormonal contraceptives and antiretrovirals concurrently. Outcomes of interest were effectiveness of either therapy, toxicity, or pharmacokinetics. We used standard abstraction forms to summarize and assess strengths and weaknesses. Results: Fifty reports from 46 studies were included. Most antiretrovirals whether used for therapy or prevention, have limited interactions with hormonal contraceptive methods, with the exception of efavirenz. Although depot medroxyprogesterone acetate is not affected, limited data on implants and combined oral contraceptive pills suggest that efavirenz-containing combination antiretroviral therapy may compromise contraceptive effectiveness of these methods. However, implants remain very effective despite such drug interactions. Antiretroviral plasma concentrations and effectiveness are generally not affected by hormonal contraceptives. Conclusion: Women taking antiretrovirals, for treatment or prevention, should not be denied access to the full range of hormonal contraceptive options, but should be counseled on the expected rates of unplanned pregnancy associated with all contra- ceptive methods, in order to make their own informed choices. Copyright Q 2017 The Author(s). Published by Wolters Kluwer Health, Inc. AIDS 2017, 31:917–952 Keywords: antiretroviral therapy, contraceptive implant, depot medroxyprogesterone acetate, HIV, hormonal contraception, systematic review Introduction Decreasing unintended pregnancies also reduces vertical HIV transmission [5].
    [Show full text]
  • Hoffmann Rockstroh |
    Hoffmann| Rockstroh HIV 2015/2016 www.hivbook.com Medizin Fokus Verlag This project has been supported with unrestriced grants from AbbVie Gilead Sciences HEXAL Janssen-Cilag MSD ViiV Healthcare By Marcus Altfeld, Hamburg/Boston (USA) Achim Barmeyer, Dortmund Georg Behrens, Hannover Dirk Berzow, Hamburg Christoph Boesecke, Bonn Patrick Braun, Aachen Thomas Buhk, Hamburg Rob Camp, Barcelona (Spain/USA) Rika Draenert, Munich Christian Eggers, Linz (Austria) Stefan Esser, Essen Gerd Fätkenheuer, Cologne Gunar Günther, Windhoek (Namibia) Thomas Harrer, Erlangen Christian Herzmann, Borstel Christian Hoffmann, Hamburg Heinz-August Horst, Kiel Martin Hower, Dortmund Christoph Lange, Borstel Thore Lorenzen, Hamburg Tim Niehues, Krefeld Christian Noah, Hamburg Ramona Pauli, Munich Ansgar Rieke, Koblenz Jürgen Kurt Rockstroh, Bonn Thorsten Rosenkranz, Hamburg Bernhard Schaaf, Dortmund Ulrike Sonnenberg-Schwan, Munich Christoph D. Spinner, Munich Thomas Splettstoesser (Figures), Berlin Matthias Stoll, Hannover Hendrik Streeck, Essen/Boston (USA) Jan Thoden, Freiburg Markus Unnewehr, Dortmund Mechthild Vocks-Hauck, Berlin Jan-Christian Wasmuth, Bonn Michael Weigel, Schweinfurt Thomas Weitzel, Santiago (Chile) Eva Wolf, Munich HIV 2015/16 www.hivbook.com Edited by Christian Hoffmann and Jürgen K. Rockstroh Medizin Fokus Verlag IV Christian Hoffmann, M.D., Ph.D. ICH Stadtmitte (Infektionsmedizinisches Centrum Hamburg) Glockengiesserwall 1 20095 Hamburg, Germany Phone: + 49 40 2800 4200 Fax: + 49 40 2800 42020 [email protected] Jürgen K. Rockstroh, M.D., Ph.D. Department of Medicine I University of Bonn Sigmund-Freud-Strasse 25 53105 Bonn, Germany Phone: + 49 228 287 6558 Fax: + 49 228 287 5034 [email protected] HIV Medicine is an ever-changing field. The editors and authors of HIV 2015/16 have made every effort to provide information that is accurate and complete as of the date of publication.
    [Show full text]
  • WO 2017/048727 Al 23 March 2017 (23.03.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/048727 Al 23 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/519 (2006.01) A61P 31/18 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 16/05 1545 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 13 September 2016 (13.09.201 6) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/218,858 15 September 2015 (15.09.2015) US kind of regional protection available): ARIPO (BW, GH, 62/382,550 1 September 2016 (01.09.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: GILEAD SCIENCES, INC.
    [Show full text]
  • 1 Anti-HIV Drug Discovery, Development and Synthesis Of
    Anti-HIV Drug Discovery, Development and Synthesis of Delavirdine: Review article Wollela Behja1 Mudin Jemal 2 1 Chemistry Department, College of Natural and Computational Sciences, Wolkite University, Ethiopia P.O.Box 07 Wolkite University, Ethiopia 2 Chemistry Department, Natural Sciences College, Jimma University, Ethiopia P.O.Box 378 Jimma University, Ethiopia ABSTRACT Viruses are the smallest infectious agents of animal and plant tissues. Viruses are totally dependent on living cells to survive as they utilize the host cell's own replication processes, in order to reproduce themselves. HIV is the causative agent of AIDS. HIV is an unusually difficult to treat because it incorporate its own genetic material into the genome of an infected host cell. It infects T cells that carry the CD4 antigen on their surface. Binding and fusion, reverse transcription, integration, transcription, assembly and budding are the major steps of the HIV life cycle. The HIV/AIDS disease is treated by interrupting the HIV life cycle with specially designed drugs. The discovery of effective drugs against HIV has focused on targeting various critical components of the replication cycle of HIV. Depending on the target within the HIV replicative cycle they interact with, anti-HIV compounds are categorized into six groups. These are: nucleoside (nucleotide) reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), cell entry inhibitors or fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The development of effective anti-HIV drugs is difficult due to wide variations in nucleotide and amino acid sequences. The development of anti-HIV drug passes through several important steps.
    [Show full text]
  • Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: a Systematic Review for the U.S
    Evidence Synthesis Number 176 Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00009-I, Task Order No. 7 Prepared by: Pacific Northwest Evidence-Based Practice Center Oregon Health & Science University Mail Code: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239 www.ohsu.edu/epc Investigators: Roger Chou, MD Tracy Dana, MLS Sara Grusing, BA Christina Bougatsos, MPH AHRQ Publication No. 18-05246-EF-1 November 2018 This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).
    [Show full text]